Leading SPO Firm Sciformix Continues Global Expansion with Opening of New Manila Office to Accommodate Rapid Growth
Sciformix Corporation, a leading Scientific Process Organization (SPO) has announced the opening of their new offices located in Manila, the Philippines. The expansion into Manila comes as part of Sciformix‘s continued growth and provides the opportunity for the company to utilise the region’s extensive resource of talented medical professionals. Philippine Labor and Employment Secretary, Rosalinda Baldoz, welcomed the move by Sciformix and the opportunity for medical professionals to remain in the Philippines with attractive salaries and career opportunities.
“Sciformix’s continued growth and success has created an opportunity for our expansion into Manila, which is an important piece of our strategy and global footprint. As a leading SPO, this move takes us forward with the goal of adding more than 200 highly skilled employees in the Philippines,” said Manish Vinayak Soman, Sciformix President and Chief Executive Officer (CEO).
Sciformix, recent winner of Frost & Sullivan’s Pharmaceutical Knowledge Process Outsourcing (KPO) Entrepreneurial Company of the Year award, has experienced remarkable growth to become an SPO, a sub-category of KPO specialising in life sciences. The company’s investment in its people and technologies has enabled the business to deliver its clients differentiated services, resulting in rapid double digit revenue growth. Sciformix has a unique positioning as a SPO, in that it combines deep expertise in workflow processes optimisation with scientific knowledge, which delivers in line with their cost efficiency model.
This expansion into the Philippines also sees Sciformix as the first company based in Manila to undertake case management activities. A 135-strong team from Sciformix’s Philippines and India centers is supporting one of its Fortune 100 company clients that specializes in consumer healthcare, medical devices and diagnostics, and pharmaceuticals.
Sciformix, headquartered in the US, with operations in India and the Philippines, partners with life science organisations through the entire drug development cycle to provide a full range of services from study design to post marketing surveillance and commercialisation support. Areas of specialisation include Safety and Risk Management, Clinical Research & Post Approval Services, Medical Affairs, Scientific Writing and Regulatory Affairs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance